Not available
Quote | Cyclacel Pharmaceuticals Inc. (NASDAQ:CYCC)
Last: | $1.75 |
---|---|
Change Percent: | -1.12% |
Open: | $1.8 |
Close: | $1.75 |
High: | $1.93 |
Low: | $1.73 |
Volume: | 24,027 |
Last Trade Date Time: | 04/22/2024 03:00:00 am |
News | Cyclacel Pharmaceuticals Inc. (NASDAQ:CYCC)
- New clinical, PK and PD data from novel CDK2/9 inhibitor fadraciclib monotherapy studies support ongoing development program in patients with solid tumors and lymphoma - BERKELEY HEIGHTS, N.J., April 01, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP;...
2024-03-19 18:09:10 ET Cyclacel Pharmaceuticals, Inc. (CYCC) Q4 2023 Earnings Call Transcript March 19, 2024, 04:30 PM ET Company Participants Grace Kim - IR Spiro Rombotis - President and CEO Brian Schwartz - CMO Paul McBarron - EVP, Finance & COO ...
Message Board Posts | Cyclacel Pharmaceuticals Inc. (NASDAQ:CYCC)
Subject | By | Source | When |
---|---|---|---|
whytestocks: $CYCC News Article - Cyclacel Pharmaceuticals Reviews 2022 Achievements and Announces K | whytestocks | investorshangout | 01/05/2023 8:30:46 PM |
Sar Pas, | Cytobeliever | investorshub | 12/06/2022 9:37:42 PM |
So what do you have to say now? | Cytobeliever | investorshub | 11/22/2022 4:50:50 PM |
whytestocks: $CYCC News Article - Cyclacel Pharmaceuticals to Present at the Ladenburg Thalmann 2022 | whytestocks | investorshangout | 09/21/2022 2:45:48 PM |
znewcar1: CYCC 26% v10,2M c1.68 f9,994M H1.72 PMH1.99 flushed S1.42 then crawled out EOD | znewcar1 | investorshangout | 08/12/2022 2:02:07 AM |
News, Short Squeeze, Breakout and More Instantly...
Cyclacel Pharmaceuticals Inc. Company Name:
CYCC Stock Symbol:
NASDAQ Market:
- New clinical, PK and PD data from novel CDK2/9 inhibitor fadraciclib monotherapy studies support ongoing development program in patients with solid tumors and lymphoma - BERKELEY HEIGHTS, N.J., April 01, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP;...
– On Track to Start Oral Fadraciclib Phase 2 Proof of Concept in 1H 2024 – – Expect to Report Final Data from Fadraciclib 065-101 Dose Escalation – – Oral Plogosertib Preclinical Data Support Precision Med...
Caleres Inc. (CAL) is expected to report $0.86 for Q4 2024 B Communications Ltd (BCOMF) is expected to report for quarter end 2023-12-31 Dermata Therapeutics Inc. (DRMA) is expected to report for Q4 2023 Core & Main Inc. Class A (CNM) is expected to report $0.34 for Q4 2024 Wi...